Cafeity Get the app

Side effects

Nausea on a GLP-1 medicine

Nausea is the side effect people on these medicines report most. It is usually worst while a dose is being increased and fades after that — but not for everyone, and not always on a predictable day. Here is what the prescribing information actually reports, why it happens, and what is worth knowing before you ring anyone.

By the Cafeity teamUpdated 8 min read

The short answer

Nausea is the most commonly reported side effect of GLP-1 medicines. In the weight-management trials it affected 44% of people on semaglutide 2.4 mg (16% on placebo), up to 29% on tirzepatide (8% on placebo), 39% on liraglutide 3 mg (14% on placebo) and up to 35% on orforglipron (10% on placebo).1234 The labels say it was most common while the dose was being stepped up, and decreased over time. Nausea that will not settle, vomiting that stops you keeping fluids down, or stomach pain that does not go away are reasons to contact a clinician.

Bar chart of nausea in the weight-management trials: semaglutide 2.4 mg 44% versus 16% on placebo; tirzepatide up to 29% versus 8%; liraglutide 3 mg 39% versus 14%; orforglipron up to 35% versus 10%.
Share of trial participants who reported nausea, from each medicine's US prescribing information. Each medicine was tested in its own trials, so these are not head-to-head comparisons — the labels themselves say rates cannot be compared across drugs.

How common it is

Every GLP-1 medicine lists nausea among its most common adverse reactions, and it is the reaction most often given as a reason for stopping. The figures below are the percentage of people in each medicine's placebo-controlled trials who reported it at least once.

Nausea in placebo-controlled trials, from the current US prescribing information. Where a label reports several doses, each dose is shown. Placebo groups received identical injections or tablets with no active drug.
Medicine (trial population)PlaceboMedicine
Semaglutide 2.4 mg weekly injection (weight management)16%44%
Semaglutide 7.2 mg weekly injection (weight management)13%39% (35% on 2.4 mg in the same trials)
Tirzepatide weekly injection (weight management)8%25% (5 mg), 29% (10 mg), 28% (15 mg)
Liraglutide 3 mg daily injection (weight management)13.8%39.3%
Orforglipron daily tablet (weight management)10%26% (5.5 mg), 34% (9 mg), 35% (17.2 mg)
Semaglutide weekly injection (type 2 diabetes)6.1%15.8% (0.5 mg), 20.3% (1 mg)
Tirzepatide weekly injection (type 2 diabetes)4%12% (5 mg), 15% (10 mg), 18% (15 mg)
Dulaglutide weekly injection (type 2 diabetes)5.3%12.4% (0.75 mg), 21.1% (1.5 mg)
Exenatide twice-daily injection (type 2 diabetes)18%44%

Two patterns stand out. Nausea was reported more often in the weight-management trials than in the type 2 diabetes trials — semaglutide and liraglutide are used at higher doses for weight management, and the populations differ. And within one medicine it tends to rise with the dose.24 It also sits inside a wider cluster: in the semaglutide 2.4 mg trials, 73% of people reported some gastrointestinal reaction, against 47% on placebo.1

Most of it is mild. In the orforglipron trials, of the people who had a gastrointestinal reaction, 60% described it as mild, 36% moderate and 4% severe; in the liraglutide trials most episodes were mild or moderate and did not lead anyone to stop.43 Severe gastrointestinal reactions were reported by 4.1% of people on semaglutide 2.4 mg injections, against 0.9% on placebo.1

Why it happens

Two mechanisms show up in the prescribing information. The first is in the stomach: these medicines slow gastric emptying, so food sits in the stomach for longer. For tirzepatide the label adds that the delay is largest after the first dose and diminishes over time.12 A fuller stomach for longer is a plausible reason a normal-sized meal can suddenly feel like too much.

The second is in the brain. GLP-1 is a natural regulator of appetite, and the receptor these medicines act on is found in several brain areas involved in appetite regulation.1 The effect people want — feeling full sooner and thinking about food less — and the effect they do not want can come from the same place.

That is also why the dose matters. The labels' recommended schedules start low and step up over weeks or months precisely to reduce gastrointestinal reactions; the orforglipron label says so in as many words.4 How fast to step up is a decision for the prescriber, never for an app.

When it tends to happen

The labels are consistent about the broad timing. For semaglutide, gastrointestinal reactions were "most frequently reported during dosage escalation". For tirzepatide, most nausea, vomiting and diarrhoea happened during dose escalation and decreased over time. For orforglipron, nausea was more common during the escalation period and decreased after it.124

Within a week, the timing is more personal. Blood levels of semaglutide peak 1 to 3 days after an injection; tirzepatide peaks at a median of about 24 hours.12 Plenty of people notice their queasiest day falls in that window. Plenty do not. Meal size, what was eaten, sleep, alcohol and another illness all move it about, which is why a few weeks of your own record says more than any general rule.

For the fuller picture of how side effects change across the first months, see when GLP-1 side effects start and how long they last.

What people commonly try

A 2025 joint advisory from four US nutrition and obesity-medicine organisations sets out practical eating strategies for people on these medicines. For nausea, it suggests:5

  • Smaller, more frequent meals rather than three large ones — a stomach that empties slowly copes better with less at a time.
  • Going easy on fatty foods, and on very high-fibre foods while the nausea is at its worst; lower-fibre fruit and vegetables are easier then.
  • Not skipping meals — eating breakfast and then something small every three to four hours, to avoid a cycle of not eating and feeling worse for it.
  • Ginger or peppermint tea, or acupressure bands, which some people find settling.
  • Anti-sickness medicine, which is a conversation for your prescriber or pharmacist.

Two more things follow from how the medicines work. Stopping at the first sign of fullness is worth practising: with the stomach emptying more slowly, a few extra mouthfuls can tip comfortable into queasy. And alcohol is worth watching: the same advisory notes it may worsen nausea and reflux on these medicines.5

None of this replaces advice from the person who prescribed the medicine. If nausea is making it hard to eat or drink, tell them — the schedule itself can be discussed.

Eating when everything looks unappealing

When appetite is low and the stomach is unsettled, the risk shifts from eating too much to eating too little — especially too little protein and fluid. Small, plain portions tend to go down more easily than large, rich ones. Many people lean on things like plain yoghurt, eggs, crackers, toast, rice, soup or a protein drink sipped slowly, and come back to fuller meals as the nausea eases.

Fluids matter most. Vomiting and diarrhoea can lead to dehydration, and the labels warn that dehydration from gastrointestinal side effects has led to kidney problems; the patient information for tirzepatide says it is important to drink fluids to help reduce the chance of dehydration.21 Small, frequent sips are easier than a large glass.

For more on getting protein in on a low-appetite day, see eating with no appetite and the printable protein food list.

When to contact your prescriber

Keeping a record of it

The useful record is not "felt sick this week" but when, how badly, and against what: the day since your dose, whether the dose changed recently, what you ate. Cafeity logs nausea with a severity and a time on the same timeline as your doses, and Ora can answer "when are my symptoms worst?" from your own entries. The Visit Summary puts it in front of your prescriber on one page.

Cafeity dose screen: an estimated medication-level curve labelled "Estimate based on published half-life. Not a measurement", the last dose, the injection site (stomach, lower left), a countdown to the next scheduled dose and a side-effect check-in.
A side-effect check-in sits under the dose record.
Cafeity "Your week, understood" screen: Ora explains that everything is calculated from your own log, offers questions such as "When are my symptoms worst?", and shows the week's protein, energy, water, weight trend, symptom days and a note that protein was 80 g under target.
Ask when symptoms tend to peak — the answer comes from your log.

Download Cafeity on the App Store

Common questions

How long does GLP-1 nausea last?
The labels describe it as most common while the dose is being increased and decreasing over time, but they give no fixed number of days or weeks, and it varies a great deal between people.24 If it is not easing, or it returns with each dose increase and is hard to live with, that is worth raising with your prescriber rather than waiting out.
Is nausea worse the day after the injection?
For some people. Semaglutide levels peak 1 to 3 days after an injection and tirzepatide at a median of about 24 hours, and many people notice their worst day falls there.12 Others see no pattern at all. A few weeks of logging will show which you are.
Does nausea mean the medicine is working?
Not in any way the labels describe. Nausea is listed as an adverse reaction, not as a sign that the medicine is working, so how sick you feel is not a useful measure of anything. If it is getting in the way, raise it with your prescriber.
Can I take an anti-sickness tablet?
Ask your prescriber or pharmacist. The joint advisory mentions anti-nausea medicines as one option clinicians use, but which one — and whether it suits you alongside your other medicines — is their call.5
Is nausea on the tablet different from the injection?
The pattern is similar. The orforglipron tablet trials reported nausea in 26% to 35% of people depending on dose, against 10% on placebo, and the semaglutide 25 mg tablet label says its common reactions were similar in type and frequency to the injection's.41

Sources

  1. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026
  2. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  3. Liraglutide 3 mg injection for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 15 June 2026
  4. Orforglipron tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 13 August 2026
  5. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society Mozaffarian D et al. 2025 (published in four journals)
  6. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice Wharton S et al. Postgraduate Medicine 2022;134(1):14–19

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.